← FDA DRUG APPROVALS

FDA ANDA · ANDA216729

LEVOTHYROXINE SODIUM

levothyroxine sodium anhydrous

Sponsor: ONESOURCE SPECIALTY

APPLICATION
ANDA216729
TYPE
ANDA
ORIGINAL APPROVAL
2025-03-05
LATEST ACTION
2025-03-05
ROUTE
INTRAVENOUS
DOSAGE FORM
POWDER
MARKETING STATUS
Prescription

Products

LEVOTHYROXINE SODIUMPrescription
LEVOTHYROXINE SODIUM 500MCG/VIAL · POWDER · INTRAVENOUS
LEVOTHYROXINE SODIUMPrescription
LEVOTHYROXINE SODIUM 100MCG/VIAL · POWDER · INTRAVENOUS
LEVOTHYROXINE SODIUMPrescription
LEVOTHYROXINE SODIUM 200MCG/VIAL · POWDER · INTRAVENOUS

Approval history

2025-03-05UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →